Publications by authors named "S Fierstein"
Article Synopsis
- AML shows diverse clinical outcomes, with those originating from hematopoietic stem cells (HSCs) being more resistant to chemotherapy.
- Research reveals that AML from HSCs contains more leukemic stem cells (LSCs) compared to AML from progenitor cells.
- Epigenetic profiling suggests that inherited programs from normal HSCs contribute to the aggressive nature of HSC-AML, with RNA polymerase II-mediated transcription posing a potential therapeutic target.
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of malignant plasma cells. Despite the development of a diverse array of targeted drug therapies over the last decade, patients often relapse and develop refractory disease due to multidrug resistance. Obesity is a growing public health threat and a risk factor for multiple myeloma, although the mechanisms by which obesity contributes to MM growth and progression have not been fully elucidated.
View Article and Find Full Text PDFArticle Synopsis
- Many inherited bone marrow failure syndromes (IBMFSs) increase the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly in the context of Fanconi anemia (FA).
- Researchers conducted gene editing on human stem cells to study mutations in MDS-related genes, revealing issues with stem cell self-renewal and differentiation linked to RUNX1 mutations.
- The findings suggest that RUNX1 mutations disrupt the cell cycle's response to DNA damage and activate immune signaling, providing a potential treatment target for restoring sensitivity to therapies in FA-associated MDS.
Endothelial cell tube formation assay is one of the most widely used and reliable methods for studying in vitro angiogenesis. Endothelial cells plated over a basement membrane extract and subjected to angiogenic factors in conditioned medium, form a rapid and quantifiable tube network within hours. Tube formation is sustained for 18-24 h, after which time apoptosis occurs and tube networks disintegrate.
View Article and Find Full Text PDFCutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in the United States, affecting one million people per year. Patients with aggressive disease have limited treatment options and high mortality, highlighting the need to identify new biomarkers linked to poor clinical outcome. HRAS mutations are found in skin papillomas and cSCCs and increase in frequency when MAP3K family members are inhibited, suggesting a link between blockade of mitogen-activated protein kinase (MAPK) signaling and initiation of RAS-primed cells.
View Article and Find Full Text PDF